TRACON Pharmaceuticals, Inc. Profile Avatar - Palmy Investing

TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the t…

Biotechnology
US, San Diego [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

TRACON Pharmaceuticals, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of TCON's Analysis
CIK: 1394319 CUSIP: 89237H209 ISIN: US89237H2094 LEI: - UEI: -
Secondary Listings
TCON has no secondary listings inside our databases.